Assessment of Frailty in Patients With Advanced Hepatocellular Cancers
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 28
- 试验地点
- 1
- 主要终点
- Percentage patients consenting for assessment out of number of patients approached
研究概览
简要总结
This study is looking at the feasibility of performing frailty assessments on patients with advanced hepatocellular cancer.
详细描述
This study is primarily looking to see if it is feasible to assess frailty in patients with advanced hepatocellular cancer. It is also evaluating whether there may be any correlation between these assessments and toxicity of treatment and outcome.
The assessments include: Frailty score, nutritional assessment, comorbidity score and quality of life. In addition sarcopenia will be assessed measuring muscle mass from imaging performed as part of routine clinical care.
The assessments will be performed at baseline on entry into the study, at week 9 and week 18.
There is the option for patients to also donate a blood samples for research purposes.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with a diagnosis of hepatocellular cancer not suitable for curative treatment
- •Seen by an oncologist or hepatologist for consideration of palliative treatment and a decision regarding management already made
- •WHO Performance status 0-2
- •Childs Pugh Score A or B
- •Written informed consent
排除标准
- 未提供
结局指标
主要结局
Percentage patients consenting for assessment out of number of patients approached
时间窗: baseline
Number of patients consenting for the study as a percentage of the number of patients approached about the study
Time taken to complete assessments
时间窗: Baseline, week 9 and week 18
Time taken to completed assessments recorded by clinical trials officer
次要结局
- Frailty as a predictor of grade 3/4 toxicity(Baseline, week 9 and week 18)
- Muscle mass and timed get up and go as predictors of outcome(Baseline, week 9 and week 18)